What's in Amarin Neuroscience Ltd's pipeline?

Amarin Neuroscience Ltd has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Amarin Neuroscience Ltd's portfolio?

Top competitors by shared drug class: Mochida Pharmaceutical Company, Ltd., Yamaguchi University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amarin-neuroscience-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Amarin Neuroscience Ltd — Portfolio Competitive Intelligence Brief

Amarin Neuroscience Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ethyl-EPA (Miraxion™)	Ethyl-EPA (Miraxion™)	phase 3	Omega-3 fatty acid / Triglyceride-lowering agent		Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Mochida Pharmaceutical Company, Ltd. · 1 shared drug class
Yamaguchi University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amarin Neuroscience Ltd:

Cite this brief

Drug Landscape (2026). Amarin Neuroscience Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amarin-neuroscience-ltd. Accessed 2026-05-16.